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Parathyroid hormone receptor 1 
(PTHR1) is a prognostic indicator  
in canine osteosarcoma
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Osteosarcoma (OS) is the most common malignant primary bone tumour in humans and dogs. Several 
studies have established the vital role of parathyroid hormone-related protein (PTHrP) and its receptor 
(PTHR1) in bone formation and remodeling. In addition, these molecules play a role in the progression 
and metastasis of many human tumour types. This study investigated the expression of PTHR1 and 
PTHrP in canine OS tissues and assessed their prognostic value. Formalin-fixed, paraffin-embedded 
tissue samples from 50 dogs diagnosed with primary OS were immunolabeled with antibodies 
specific for PTHR1 and PTHrP. The immunostaining intensity of tumours from patients with OS was 
correlated with survival time. Both PTHR1 and PTHrP were detected in all OS samples (n = 50). Dogs 
with OS tumours showing high immunostaining intensity for PTHR1 (n = 36) had significantly shorter 
survival times (p = 0.028, Log Rank; p = 0.04, Cox regression) when compared with OS that had low 
immunostaining intensity for PTHR1 (n = 14).PTHrP immunostaining intensity did not correlate with 
survival time (p > 0.05). The results of this study indicate that increased expression of PTHR1 antigen 
in canine OS is associated with poor prognosis. This suggests that PTHR1 may be useful as a prognostic 
indicator in canine oS.
Osteosarcoma (OS) is a malignancy that originates from bone-forming mesenchymal cells1. It is the most preva-
lent type of primary bone cancer in both humans and dogs2–5. Canine OS represents 85–98% of all canine primary 
bone cancers and occurs more commonly in appendicular skeleton (75%)6. In the USA, more than 10,000 cases 
of canine OS are reported every year7.
In the last 35 years, there has been little improvement in the treatment of human OS or its prognosis after 
treatment with surgery and chemotherapy, especially for patients with metastatic OS8. It has been found that the 
median survival times of dogs suffering from OS and receiving standard care (surgery and adjuvant chemother-
apy) is from three months to one year and that less than 20% will be alive more than two years after diagnosis9. 
So, there is a need to identify indicators for early diagnosis and prediction of prognosis in OS which may assist in 
improvement of patient survival.
Parathyroid hormone-related protein (PTHrP) was discovered as the factor responsible for causing hyper-
calcemia of malignancy in some tumours10. Parathyroid hormone (PTH) and PTHrP share a similar amino acid 
sequence in the N-terminal region10. That allows the two to activate a common G-protein coupled receptor known 
as PTH/PTHrP receptor (PTHR1)11. PTHrP and its receptor are highly conserved amongst all vertebrates12.
PTHrP is produced in many normal tissues where it acts as an autocrine/paracrine regulator of cell growth, 
development and differentiation13. In addition, PTHrP has been localised in numerous human cancers including 
breast cancers14, neuroendocrine cancers15, prostate cancers16, squamous cell carcinoma of skin17, pancreatic ade-
nocarcinoma18, intrahepatic cholangiocarcinoma19 and OS20. Several studies showed that PTHrP is also produced 
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by canine tumours such as thyroid carcinoma, multiple myeloma, anal gland adenocarcinomas21, mammary 
gland carcinoma22, thyroid carcinoma23, histiocytic sarcoma and renal cell carcinoma24.
Recently, Hastings et al.25 revealed that increased expression of PTHrP was associated with poor prognosis in 
lung carcinoma. In addition, secretion of PTHrP by tumour cells may be involved in metastasis and in the regu-
lation of primary breast tumour growth26.
PTHR1 is a member of the class B G-protein coupled receptor (GPCR) family27. Several studies carried out 
using human tissues28, mice29 and cell lines30 have noted the association between PTHrP/PTHR1 expression and 
OS. Yang and his group30 suggested that over-expression of PTHR1 may stimulate human OS progression via 
formation of a more aggressive phenotype. Furthermore, Ho and colleagues29 demonstrated that knockdown 
of PTHR1 in murine OS cells reduced growth and invasion and increased tumour differentiation. Recently, a 
study has shown that PTHrP is an essential factor for initiation, hyperproliferation and maintenance of murine 
p53-deficient OS31. The authors found that PTHrP activated PTHR1 and increased cAMP leading to cAMP 
response element-binding protein 1 (CREB1) phosphorylation and transcriptional activation31. Walia et al.31 
concluded that PTHrP-cAMP-CREB1 axis was crucial for initiation of murine OS in p53-deficient osteoblasts.
Previously, it was shown that if PTHR1 expression in vivo was decreased, then OS had enhanced minerali-
sation and differentiation29. In addition, Ho et al.29 found that levels of PTHrP were higher in the osteoblastic 
histological subtype of murine OS compared to the less aggressive subtype. However, PTHR1 and PTHrP were 
not investigated in canine OS and there is no data about their association with survival time.
To further evaluate the prognostic value of PTHR1 and PTHrP in OS, their expression was investigated in the 
naturally occurring canine OS. The study also examined whether such expression was associated with survival.
Results
Clinical and epidemiological data. Fifty canine primary OS samples (ASAP-50) were collected prospec-
tively from the Australian Specialised Animal Pathology (ASAP) laboratory and the data were obtained inde-
pendently (Table 1). The age ranged from 1 to 15 years with a mean and median age of 9 years and males (30 dogs, 
60%) were predominant. Thirty dogs (60%) were of a pure breed and 20 (40%) were of mixed breed. There were 
42 (84%) dogs of large or medium breeds and eight (6%) of small breeds. The frequency of the top two repre-
sented breeds was Labrador (five dogs, 10%) and Rottweiler (five dogs, 10%). Tumours were located mostly in the 
humerus (13 dogs, 26%), jaw (eight dogs, 16%) and radius (seven dogs, 14%) (Table 1).
Histopathology. The histopathological review classified osteoblastic OS (33 dogs, 66%) as the most common 
subtype of canine OS while, chondroblastic (11 dogs, 22%) and fibroblastic (six dogs, 12%) OS were less frequent 
(Supplementary Table S1). Twenty-seven canine OS tumours (54%) were graded as G1 and 23 tumours (46%) as 
G2 (Table 1).
PTHR1 immunostaining intensity in canine OS. PTHR1 was detected in all cases (n = 50). PTHR1 
showed low immunostaining intensity in 14 (28%) cases (Fig. 1A, C: non-immune control) and high immunos-
taining intensity in 36 (72%) cases (Fig. 1B, D: non-immune control) (Table 1). Cytoplasmic plus nuclear local-
isation of PTHR1 was observed in the neoplastic cells in all cases. There was no significant association between 
PTHR1 immunostaining intensity and the clinicopathological data (age, gender, breed, tumour grade) (p > 0.05, 
Chi-Square test).
PTHrP immunostaining intensity in canine OS. PTHrP was localised in the all canine OS sections 
(n = 50). Low immunostaining intensity of PTHrP was detected in 25 (50%) cases (Fig. 1E) and high immunos-
taining intensity in 25 (50%) cases of canine OS (Fig. 1F) (Table 1). PTHrP was localised to the cytoplasm of neo-
plastic cells in 33 (66%) cases and to the nucleus plus the cytoplasm in 17 (34%) cases. There was no significant 
difference in PTHrP immunostaining intensity between dogs with different ages at diagnosis, genders, breeds 
and tumour grades (P > 0.05, Chi-Square test). PTHR1 and PTHrP immunolabelling of normal canine kidney 
tissue revealed strong cytoplasmic positivity in proximal and distal tubules, in contrast to weak immunolabelling 
in glomeruli28,32.
Supplementary Figs. S1 and S2 show western blot analysis of PTHrP expression in canine OS.
High immunostaining intensity of PTHR1 in canine OS (ASAP-50) correlates with decreased survival 
time and may act as a prognostic indicator. To investigate the relationship between immunostaining 
intensity of PTHR1 and the survival times of dogs with OS, the survival times for dogs with OS showing high 
immunostaining intensity of PTHR1 were compared to survival times for those showing low immunostaining 
intensity. Dogs with OS showing high immunostaining intensity for PTHR1 had shorter average survival times 
(mean = 139 ± 27 days) compared to those with low immunostaining intensity (mean = 290 ± 68 days). This dif-
ference was significant (p = 0.028, Log Rank; n = 50; 95% confidence interval (CI), 127.2–240.4) (Fig. 2A).
There was no significant difference between PTHrP immunostaining intensity and survival times (p = 0.782, 
Log Rank; n = 50, 95% CI, 127.2–240.4).
The univariate Cox regression analysis identified that high immunostaining intensity of PTHR1 in dogs with 
OS (p = 0.032, n = 50; univariate Cox regression, 95% CI, 0.218–0.935) was predictor for poor prognosis. Other 
variables such as expression of PTHrP, age, gender, breed and tumour grade did not show any significant prog-
nostic value (p > 0.05). In addition, multivariate Cox regression analysis showed that immunostaining intensity 
of PTHR1 is an independent significant prognostic indicator for canine OS (p = 0.040, n = 50; multivariate Cox 
regression, 95% CI, 0.172–0.961).
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1 Staffordshire Bull Terrier F 12 Humerus 1 28* Low Low
2 Greyhound M 10 Tibia 1 90 High High
3 Rottweiler M 1 Humerus 1 114 High Low
4 Boxer Cross M 11 Femur 1 458 Low Low
5 Mastiff F 7 Rib 1 14* Low Low
6 Bulldog M 10 Tibia 1 193 Low Low
7 Labrador Retriever M 8 Radius 1 702 Low Low
8 Giant Schnauzer M 7 Radius 2 380 High High
9 Boxer F 10 Rib 2 240* Low Low
10 German Shepherd Dog F 11 Radius 2 485 High High
11 Rottweiler Cross F 8 Jaw 1 83* High High
12 Spoodle M 10 Rib 2 71* High Low
13 Schnauzer Cross M 11 Rib 2 4* Low Low
14 Doberman F 10 Tibia 1 240 High Low
15 Rottweiler M 8 Humerus 1 150* High Low
16 Rottweiler F 9 Jaw 1 157* High Low
17 Golden Retriever M 8 Humerus 1 65* Low Low
18 Golden Retriever M 14 Femur 2 115* High High
19 Rottweiler Cross M 9 Ilium 1 1* High Low
20 Doberman M 9 Radius 1 104* Low Low
21 Labrador F 7 Radius 2 277 Low Low
22 Jack Russell Terrier M 8 Jaw 2 21* High Low
23 Rottweiler F 4 Humerus 2 96 High Low
24 Blue Heeler M 12 Tibia 1 150* High High
25 Golden Retriever M 13 Jaw 1 180* Low High
26 Mastiff Cross M 6 Femur 2 470 Low Low
27 Cairn Terrier F 12 Humerus 1 155 High High
28 Boxer Cross F 15 Jaw 1 43* High High
29 Jack Russell Terrier F 9 Scapula 2 27* High High
30 Labrador M 11 Humerus 1 578 High High
31 Cavalier Cross M 10 Humerus 2 26 High High
32 Labrador M 13 Jaw 2 21* High High
33 Border Collie M 6 Femur 2 17* High Low
34 Labradoodle M 3 Rib 2 11* High High
35 Pointer Cross F 9 Radius 1 17* High Low
36 Rottweiler Cross F 9 Humerus 2 270 High Low
37 Border Collie Cross F 13 Scapula 2 135* Low Low
38 American Staffordshire Bull Terrier M 12 Vertebrae 1 54* High Low
39 White Swiss Shepherd Dog F 9 Ilium 2 3* High High
40 Maltese Cross M 13 Jaw 2 47* High High
41 SBT Cross F 9 Humerus 2 76 High High
42 Alaskan Malamute M 6 Radius 1 82 High Low
43 Rottweiler F 11 Tibia 2 288 High High
44 Curly Coated Retriever F 11 Humerus 1 90 High High
45 Boxer F 7 Skull 1 24* High High
46 Labrador M 8 Humerus 2 14* High High
47 Jack Russell Terrier M 14 Jaw 2 154* High High
48 Labrador M 7 Femur 1 7* High High
49 Greyhound M 11 Femur 1 655 Low High
50 Labradoodle M 7 Humerus 1 142* High High
Table 1. Clinicopathological data and immunostaining intensity of PTHR1 and PTHrP for those cases 
collected from ASAP laboratory with survival time (ASAP-50). *Cases excluded from the larger ASAP-50 group 
of dogs with OS to make a homogenous group (ASAP-20). Excluded dogs had no surgical or no chemotherapy, 
or had pulmonary metastasis at presentation, or presented with OS localised in axial parts, or still alive at the 
date of data collection, or died because of post-surgical complications; SBT, Staffordshire Bull Terrier; F, female; 
M, male.
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High PTHR1 immunostaining intensity correlates with reduced survival time and acts as a 
prognostic indicator for the smaller group of dogs with OS (ASAP-20). In order to minimise var-
iation in the population and validate the findings presented above, dogs that had no surgical (24 dogs) or no 
chemotherapy treatments (26 dogs), or had pulmonary metastasis at presentation (four dogs), or presented with 
OS localised in axial parts (15 dogs), or were still alive at the date of data collection (three dogs), or died because 
of post-surgical complications (four dogs) were excluded from survival analyses (Table 1). The remaining 20 dogs 
(40%) with appendicular OS (ASAP-20) had limb amputation and then went through adjuvant chemotherapy 
using cisplatin or carboplatin as a single or multiple dose, had no pulmonary metastasis and died due to OS. The 
survival times for dogs with OS showing high PTHR1 immunostaining intensity and for those with OS showing 
low PTHR1 immunostaining intensity were compared.
The Log Rank test showed that there was a significant difference in the survival time between groups of 
dogs with appendicular OS showing high and low immunostaining intensity of PTHR1 (p = 0.030; n = 20; 95% 
CI: 194.6–377.9) (Fig. 2B). Dogs with appendicular OS showing high PTHR1 immunostaining intensity had 
shorter average survival times (mean = 212 ± 45 days) compared to those with low immunostaining intensity 
(mean = 459 ± 82 days) (Fig. 2B).
Moreover, the prognostic value of PTHR1 immunostaining intensity for overall survival in the smaller group 
of dogs with appendicular OS (ASAP-20) was analysed using the univariate Cox regression analysis on different 
clinicopathological parameters, including breed size, sex, age, tumour grade and PTHrP immunostaining inten-
sity. The analysis showed that PTHR1 immunostaining intensity was the only parameter that influenced sur-
vival rates (p = 0.040, univariate Cox regression; n = 20; 95% CI: 0.099–0.948). Other variables including breed 
size, sex, age, tumour grade and PTHrP immunostaining intensity did not show any significant prognostic value 
(p > 0.05).
A multivariate Cox regression analysis was used to further evaluate the prognostic value of PTHR1 immu-
nostaining intensity in canine OS prognosis. The analysis revealed that PTHR1 immunostaining intensity was 
an independent prognostic factor for overall survival (p = 0.040, multivariate Cox regression; n = 20; 95% CI: 
0.172–0.961). Thus, the findings also suggest that the immunostaining intensity of PTHR1 is significantly linked 
with the prognosis of canine OS.
Discussion
OS is the most prevalent primary bone cancer in humans and dogs2–5. Despite the current treatment consisting 
in surgery and adjuvant chemotherapy, OS bears a poor prognosis33. Identification and characterisation of novel 
markers that could assess possible survival time might allow for better categorisation of patients for risk-based 
treatment. PTHR1 and PTHrP have not been investigated as prognostic indicators in either canine or human OS 
and until now the presence of PTHR1 and PTHrP has not been investigated in naturally occurring canine OS.
The aim of this study was to determine the expression of PTHR1 and PTHrP in canine OS tissues at the 
cellular level and to investigate whether this immunostaining intensity had any prognostic value. PTHR1 was 
detected in 100% of canine OS. To better evaluate the prognostic value of PTHR1and PTHrP, the survival times 
of dogs with high immunostaining intensity tumours were compared with those that had low immunostaining 
intensity tumours. Univariate and multivariate analyses revealed that immunolabelling of PTHR1 is a significant 
prognostic indicator in dogs with OS. Dogs with high immunostaining intensity OS tumours for PTHR1 were 
characterised by a significantly shorter survival time than those with low immunostaining intensity tumours. In 
addition, no significant correlation was observed between immunostaining intensity of PTHrP and survival times 
for dogs with OS. To the best of our knowledge, this is the first study to show the negative correlation of PTHR1 
in canine OS with survival time.
PTHR1 was first localised at the cellular level in human OS and 17 other tumours and their tissues of origin 
using Western blot and IHC in 201028. Lupp and others28 found that PTHR1 was present in 50% (n = 4) of human 
OS. In addition, a recent study showed that PTHR1 was expressed in mouse OS cells29. In the same study, Ho and 
colleagues29 found that knockdown of PTHR1 in murine OS cells increased tumour differentiation and reduced 
cell growth and invasion. Furthermore, a previous research revealed that overexpression of PTHR1 in human 
OS xenografts was correlated with increased proliferation, cell migration and invasion30. However, expression 
of PTHR1 was also detected in human OS cell lines (OS160, OS164, OS166, OS187 and OS191) derived from 
patients, but at a low level30. Moreover, these authors found that tissue of metastatic human OS had high expres-
sion of PTHR1 mRNA compared with the tissue from the primary tumour30. Collectively, these studies support 
our hypothesis that increased amounts of PTHR1 in OS may be correlated with poor prognosis.
Our findings also demonstrated that similar to PTHR1, PTHrP was detected in 100% of canine OS. The cur-
rent study found that dogs with low immunostaining intensity tumours for PTHrP did not have a significantly 
longer survival time when compared with dogs that had high immunostaining intensity tumours.
Number of studies in rat and mouse OS cell lines reported the expression of PTHrP29,34. Yang and colleagues30 
found that PTHrP mRNA was not detected in aggressive human OS xenografts. Although we did not examine 
gene expression, one could extrapolate that the increase in protein might be a result of increased gene expression. 
It has been shown that overexpression of the PTHrP gene is correlated with reduced cell proliferation using a 
murine OS cell line35. This was supported by work that overexpression of PTHrP in a rat OS cell line was also 
associated with decreased growth rate36.
On the other hand, a study was conducted using the Saos-2 human OS cell line37, in which PTHrP-induced 
tumour cells became resistant to chemotherapy via the inhibition of major apoptosis signaling pathways by block-
ing the death receptor and mitochondria-mediated apoptosis signaling. In addition, Berdiaki and colleagues38 
found that PTHrP stimulates migration of MG-63 and Saos 2 human OS cell lines. The last two studies37,38 
suggested that increased amounts of PTHrP may be associated with shorter survival time. Recently, Walia and 
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Figure 1. Immunohistochemical staining for PTHR1 and PTHrP in canine OS. Positive and negative 
cells could be seen in both the tumour and the osteoid areas. (A) Neoplastic cells are characterised by low 
cytoplasmic plus nuclear immunostaining intensity for PTHR1. (B) Neoplastic cells are characterised by high 
cytoplasmic plus nuclear immunostaining intensity for PTHR1. (C, D) Non-immune control for the above 
cases. Neoplastic cells are characterised by absent cytoplasmic or nuclear immunolabelling for PTHR1.  
(E) Neoplastic cells display low cytoplasmic immunostaining intensity for PTHrP. (F) Neoplastic cells display 
high cytoplasmic plus nuclear immunostaining intensity for PTHrP. (G, H) Non-immune control for the 
above cases. Neoplastic cells are characterised by absent cytoplasmic or nuclear immunolabelling for PTHrP. 
Immunohistochemistry. Mayer’s haematoxylin counterstaining.
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others31 revealed that PTHrP is crucial to initiate OS in murine p53-deficient osteoblasts. The researchers showed 
that PTHrP binds to PTHR1 which stimulates production of cAMP, resulting in phosphorylation of CREB1 and 
activation of transcription in p53-deficient OS31. This may explain the detection of high immunostaining intensity 
of PTHrP and PTHR1 in the most of OS tissues in the present study.
The present study demonstrated cytoplasmic and nuclear localisation of both PTHR1 and PTHrP. It has been 
shown that PTHR1 is transported to the nucleus after binding to the transport regulatory proteins, importin α1 and 
importin β39, while PTHrP binds to importin β40. Pickard et al.39 found that PTHR1 was overexpressed in the nucleus 
during early interphase stage (G0/G1, S, and G2 phases) of the cell cycle using MC3T3-E1 mouse non-transformed 
osteoblasts, SaOS-2 human OS and ROS 17/2.8 rat OS cell lines. In these early stages, the DNA is known to be open to 
transcriptional activity comparing to the late stages where the DNA is compact and transcriptional activities are very 
less and the immunostaining intensity of PTHR1 is low39. In tumours, the abundant nuclear localisation of PTHR1 
could be explained by the increased rate of neoplastic cell mitosis and most of these cells are at the early stages.
Recently, it was suggested that PTHrP stimulates matrix mineralisation and proliferation of osteoblasts 
through three mechanisms: an autocrine/paracrine signal-peptide/PTHR1-dependent mechanism, an intracrine 
nuclear localisation signal-dependent mechanism and mixed mechanism41. Even though associated with stimu-
lating proliferation and reducing apoptosis in certain cell types, the exact role of PTHrP in the nucleus/nucleolus 
still unclear42.
Furthermore, Walkley et al.43 suggested the pathway of PTHR1 in OS carcinogenesis. Normally, the PTHR1 
located on the surface of normal osteoblasts is activated via binding to PTHrP. Activation of PTHR1 resulted 
in the synthesis of cyclic adenosine 3′,5′-monophosphate (cAMP) from ATP by adenylyl cyclase. Thus, cAMP 
induces the release of cAMP-dependent protein kinase A (PKA) from its α regulatory subunit of PKA type 1 
(PRKAR1A). After that, triggered PKA enter into the nucleus to phosphorylate and activate cAMP response 
element-binding protein 1 (CREB1). This leads to activate the signaling of target gene downstream of PTHR143. In 
OS, numerous defects in the PTHrP-PTHR1-PKA pathway rise the activity of PKA pathway including increased 
expression of Prkaca gene that encodes catalytic component of PKA and amplified number of PTHR1 on the cell 
surface. In addition, other defects are mutations in Prkar1a gene and increased production of PTHrP. The muta-
tion of Prkar1a gene leads to increase the activity of PKA, while increased production of PTHrP which can bind 
to PTHR1 and stimulate the formation of cAMP43. Recently, Li et al.44 proposed that the effects of PTHR1 could 
be mediated by triggering angiogenesis, inflammation and Wnt pathways through altering the expressions of the 
crucial enriched genes (Dkk1, Lef1, Agt-CCR3, and Agt-CCL9) using mouse OS cells.
The current study did not detect any significant prognostic value for other variables such as age, gender, breed 
or tumour grade. Similar findings were reported by some previous studies45–49.
The effects of the decalcification were not controlled in this study. Canine kidney (without decalcification) 
was used as the normal control tissue and was routinely immunostained with the canine OS samples. In our 
experience, decalcification lowers the amount of immunostaining seen in the tissues, but we have taken this into 
account during the optimization of IHC. According to the available data in the current study, the duration of 
decalcification had limited effect on the staining intensity of PTHR1 and PTHrP.
In the current study, the cause of death was assumed to be OS unless it was obviously otherwise. Cause of 
death determination is complex. The standard for most of cancer studies is to assume the worst-case scenario. 
This is reasonable as OS has a high metastatic rate. In most cases, metastases were observed on repeated imaging. 
In a few cases, like the one assumed to have developed a brain lesion, we assumed that it was metastatic OS since 
this was the most reasonable assumption.
In conclusion, this study localised PTHR1 and PTHrP in canine OS. Moreover, it has demonstrated that low 
immunostaining intensity of PTHR1 in canine OS related to a better prognosis, while high immunostaining 
intensity of PTHR1 is correlated with decreased survival time and it is a significant indicator for poor prognosis.
Figure 2. Kaplan-Meier survival analysis of canine OS with high and low immunostaining intensity of PTHR1. 
(A) Dogs (ASAP-50 group) with tumours showing high immunostaining intensity of PTHR1 (139 ± 27 days, 
n = 36) had shorter survival times compared to dogs with tumours showing low immunostaining intensity 
(290 ± 68 days, n = 14) (P = 0.028, Log Rank test; n = 50). (B) Dogs (ASAP-20 group) with tumours showing 
PTHR1 high immunostaining intensity (212 ± 45 days, n = 14) had shorter survival times compared to dogs 
with tumours showing low immunostaining intensity (459 ± 82 days, n = 6) (P = 0.030, Log Rank test; n = 20).
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Methods
Canine tumour specimens. A total of 50 formalin-fixed, paraffin-embedded (FFPE) canine OS tissues 
reported between 2014 and 2016 at the Australian Specialised Animal Pathology Laboratory (ASAP), Mulgrave, 
Victoria, Australia were available for this study (ASAP-50 group) (Table 1). These samples were collected pro-
spectively. To minimise variation in the samples, patients with axial affected parts (24%), or had no surgical or 
no chemotherapy treatments (22%), or had pulmonary metastasis at presentation (6%), or still alive at the date of 
data collection (4%), or died because of surgery post-complication (4%) were excluded from this study. The sur-
vival times were analysed for the ASAP-50 group and for the remaining 20 patients (40%) (ASAP-20group). The 
samples were submitted from the following veterinary clinics/hospitals Southpaws Specialty Surgery for Animals 
(16 cases), Advanced Veterinary Care (three cases), Gasing Veterinary Clinic (three cases), Preston Veterinary 
Clinic (three cases), Glenhuntly Road Veterinary Clinic (two cases), Hampton Veterinary Hospital (two cases), 
Knox Veterinary Clinic (two cases), Northcote Plaza Veterinary Clinic (two cases), Prahran Veterinary Hospital 
(two cases), Boronia Veterinary Clinic (one case), Burvale Heights Veterinary Hospital (one case), Canterbury 
Veterinary Clinic (one case), Care Collingwood (one case), Carnegie Veterinary Clinic (one case),Endeavour 
Hills Veterinary (one case), Ferntree Gully Veterinary (one case), Maroondah Veterinary Clinic (one case), 
Mitcham Pet Hospital (one case), Old Sale Road Veterinary (one case), Tarwin Veterinary Group (one case), 
Warby Street Veterinary Hospital (one case), West Gippsland Veterinary Care (one case), Westernport Veterinary 
Group (one case) and Yarrambat Veterinary Hospital (one case). The diagnosis of OS was confirmed according 
to the World Health Organization (WHO) classification50 and the tumour grading was performed according to 
Enneking et al.51.
An application was submitted to RMIT University Animal Ethics Committee. Because the tissue collected in 
the normal course of treatment and not specifically for the purposes of research, it did not meet the definition 
of scientific procedure within the legislation of Australian code for the care and use of animals for scientific pur-
poses, 8th edition (2013). As a result, Animal Ethics Committee approval for this project was not required and 
informed consent was needed from the treating veterinarians.
The 20 dogs with appendicular OS (ASAP-20) included were treated surgically (amputation) followed by 
adjuvant chemotherapy with a single or multiple dose of cisplatin or carboplatin (Supplementary Table S1). All 
canine OS specimens (ASAP-50) included were decalcified using hard decal fluid (formic acid 9.8%, hydrochloric 
acid 8.46%) (Australian Biostain, Traralgon, Australia) or decal fluid (formic formal saline - formaldehyde BP 4%, 
formic acid 33%, sodium chloride 0.85%) (Australian Biostain, Traralgon, Australia). The decalcification time 
depends on the hardness and size of the bone biopsy and ranges from one hour to three weeks.
Data for metastasis were gathered from veterinary clinics and dog’s histopathology diagnostic report 
(Supplementary Table S1). Survival data and treatment regimens were obtained by contacting the treatment vet-
erinary clinics. Dogs were followed up through intermittent visits to the treating veterinarians but not by X-rays 
or blood tests.
Immunohistochemistry. Immunohistochemical staining (IHC) was performed with PTHR1 and PTHrP 
antibodies on all cases (n = 50). The IHC method was modified from Rosol et al.52. Paraffin tissue decalcified 
blocks were received from the ASAP Laboratory and sections (3 μm) were cut using a microtome (RM2235, Leica, 
Mt Waverly, Australia). Tissue sections were fixed on positively charged glass microscope slides (Superfrost Plus) 
(Trajan Scientific, Ringwood, Australia). Sections were incubated in high pH retrieval solution (pH 9.0, code: 
9511, CINtec, Newcastle, Australia) and placed into PT Link (Dako, Sydney, Australia) at 97 °C for 20 minutes. 
After that, sections were treated with 1% Triton X-100 (code: 17–1315–01, Amersham Biosciences, Uppsala, 
Sweden) for 30 minutes to improve antibody penetration, then 3% hydrogen peroxide (Biotech Pharmaceuticals, 
Laverton North, Australia) for 10 minutes to block endogenous peroxidase and 0.4% casein block (Instant Skim 
Milk Powder, Coles Supermarkets, Hawthorn East, Australia) for 30 minutes to block the non-specific binding 
sites53. Next, the sections were incubated with primary polyclonal antibodies (PTHR1, Sc-20749, dilution: 1 in 
50, Santa Cruz, Scoresby, Australia) (PTHrP, Sc-9680, dilution: 1 in 50, Santa Cruz, Scoresby, Australia) (Envision 
FLEX (Antibody diluent) code: K8006, Dako, Sydney, Australia) for 1 hour and their respective secondary anti-
bodies (rabbit anti-goat polyclonal antibody, P0449, dilution: 1 in 100, Dako, Sydney, Australia) (Dual Link 
System-HRP, K4061, dilution: ready to use, Dako, Sydney, Australia) for 30 minutes. Then, the sections were 
incubated with 3, 3′-diaminobenzidine (DAB) (Dako, Sydney, Australia) for 10 minutes to visualise and localise 
the targeted proteins. Finally, the slides were counterstained with Mayer’s haematoxylin (Amber Scientific, Perth, 
Australia), dehydrated, cleared and mounted under DPX (Grale Scientific, Ringwood, Australia). Test slides were 
run in duplicate with a non-immune control. Normal canine kidney tissue was used as a positive control28,32. 
Primary antibody control (no antibody) (negative reagent control, 9511, CINtec, Newcastle, Australia) was car-
ried out on canine OS samples and canine normal kidney tissue. Immuno-stained tissue sections were micro-
scopic assessed manually and sections with non-specific stain or with a background of moderate (+2) or strong 
(+3) immunostaining intensity were run again.
Quantitative analysis of immunohistochemical staining. Digital whole slide images were produced 
at an absolute magnification of ×400 using the Aperio ScanScope XT Digital Pathology Slide Scanner System at 
Austin Health, Heidelberg, Victoria, Australia (Leica Microsystems, Sydney, Australia). Each whole slide image 
was annotated to select tumour areas. Localisation and intensity of immunostaining of PTHR1 and PTHrP were 
analysed quantitatively in six fields of representative tumour areas. The Cytoplasmic v2 spectrum analysis algo-
rithm package was applied to calculate the percentage of immunolabeled cells and to measure the immunostain-
ing intensity for each tumour using ImageScope analysis software.
The quality of the digital images that were produced for whole tissue sections was evaluated. The threshold for 
each stain was specified by the ImageScope software and the percentage area of positive staining was calculated 
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by an algorithm based on a de-convolution method to separate the stains. Each pixel was classified according to 
the number of stained cells present and according to location of the positive stain (nuclear, membrane or cyto-
plasmic). During the selection of the six representative tumour fields for each slide, areas with osteoid or other 
non-tumour tissues were avoided in “marking up” the stained section. In addition, osteoid was excluded from 
analysis using negative pen tool.
The H-score was calculated using ImageScope viewer (version 10, Aperio Technologies, Leica Microsystems, 
Sydney, Australia). The H-score is calculated using the following equation: (3 × percentage of strongly immu-
nostaining nuclei/cytoplasm + 2 × percentage of moderately immunostaining nuclei/cytoplasm + percentage of 
weakly immunostaining nuclei/cytoplasm). The range of the final score is from 0 to 300, where 300 equivalent 
to 100% of tumour cells with strong intensity54. Tumours with H-score from 0 to 2 were considered negative. 
Tumours with H-score from 2 to 150 were considered low immunostaining intensity and from 151 to 300 were 
considered high immunostaining intensity.
Before the Aperio scanning and the calculation of H-score, slides were manually scanned and scored. The data 
of manual scoring is not included in the manuscript. A modified immunoreactive score (IRS) system was used 
in the manual scoring method to score the IHC stained slides with anti-PTHR1 and anti-PTHrP. The IRS (0–12) 
of each slide was calculated by multiplying the estimated staining intensity (0, 1, 2, 3) by the estimated propor-
tion of tumour cells with positive staining (0, 1, 2, 3, 4). Tumour immunostaining with scores from 1 to 6 were 
considered weakly positive and scores from 7 to 12 were considered strongly positive, while tumour with score 0 
were negative. The categorization of tumours as weak and strong immunostaining intensity was similar with both 
manual and quantitative scoring.
Statistical analysis. IHC results, clinicopathological data such as age, gender, breed and tumour grade, and 
survival time were compared and analysed using Chi-Square test (IBM SPSS Statistics 24). The Kaplan-Meier 
method was used to generate the survival curves. Log Rank test was performed to measure the differences in sur-
vival that occurred over the time for dogs with OS. The survival analysis was performed considering the following 
variables: presence of PTHR1 and PTHrP, age, gender, breed and tumour grade. In addition, univariate and mul-
tivariate analyses were performed using Cox regression (proportional hazard analysis) to analyse potential prog-
nostic indicators. The examined indicators were expression of PTHR1 and PTHrP, age, gender, breed and tumour 
grade. Survival time was defined as the number of days between surgery and death because of OS. Censored data 
were considered those cases that died during the surgery or as a result of postoperative complications or other 
non-cancer related causes. The data were described using mean ± standard error, (95% confidence interval (CI)) 
and P < 0.05 was considered significant.
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